Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

BACKGROUND: In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC). METHODS: Patients received oral regorafenib 60–220 mg daily (160 mg daily in th...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Strumberg, D, Scheulen, M E, Schultheis, B, Richly, H, Frost, A, Büchert, M, Christensen, O, Jeffers, M, Heinig, R, Boix, O, Mross, K
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2012
Ämnen:
Clinical Study
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3364125/
https://ncbi.nlm.nih.gov/pubmed/22568966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.153
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk